PPP1R14D Antibody

What is PPP1R14D and what is its biological function?

PPP1R14D functions as an inhibitor of protein phosphatase 1 (PP1). The protein not only determines substrate specificity of PP1 but is also activated through PKC phosphorylation to become an effective inhibitor of protein phosphatase . In normal cellular physiology, PPP1R14D acts as a molecular switch for regulating the phosphorylation status of PP1CA substrates and smooth muscle contraction . It's important to note that PPP1R14D has inhibitory activity only when phosphorylated, creating a regulatory mechanism for controlling PP1 activity . PP1 itself is a critical Ser/Thr protein phosphatase involved in numerous cellular processes including cell division through dephosphorylation by removing phosphate groups on Ser/Thr residues .

What is the tissue distribution pattern of PPP1R14D?

PPP1R14D is normally widely expressed in the brain and intestine . When investigating PPP1R14D expression in tissues, researchers can use antibodies for immunohistochemistry applications. Several commercial antibodies have demonstrated positive reactivity in colon tissues (both mouse and rat) . This tissue specificity should be considered when designing experiments involving PPP1R14D detection or functional analysis, especially when studying its role in different organ systems or comparing its expression between normal and pathological tissues.

What applications can PPP1R14D antibodies be used for?

PPP1R14D antibodies are suitable for multiple research applications:

• Western Blot (WB): Typically used at dilutions between 1:500-1:2000

• Immunohistochemistry (IHC): Recommended dilutions around 1:100-1:300

• Immunofluorescence (IF): Effective at dilutions of 1:50-200

• ELISA: Can be used at higher dilutions of 1:5000

• Immunocytochemistry (ICC): Available with specific antibody products

When selecting an application, consider that each requires different sample preparation methods and optimization. For instance, IHC protocols typically involve antigen retrieval steps such as high-pressure heat treatment in sodium citrate solution (pH 6.0) followed by blocking with serum to prevent non-specific binding .

How does PPP1R14D contribute to cancer development and progression?

Recent studies have revealed that PPP1R14D may play a carcinogenic role in multiple tumor types. In lung adenocarcinoma (LUAD), PPP1R14D is highly expressed and promotes cell proliferation, migration, and invasion . Mechanistic analyses indicate that PPP1R14D knockdown inhibits these cancer-promoting processes by inactivating the PKCα/BRAF/MEK/ERK pathway signaling and its downstream key proteins including c-Myc/Cyclin E1-CDK2 and MMP2/MMP9/Vimentin .

Research has demonstrated that:

• PPP1R14D expression negatively correlates with patient age and positively correlates with advanced cancer staging in LUAD

• Higher expression levels are associated with lower survival rates in LUAD patients

• PPP1R14D knockdown suppresses tumor growth in vivo

• In pancreatic cancer, PPP1R14D may be activated through hypomethylation of proto-oncogenes

• PPP1R14D has been implicated in inducing metalloproteinase ADAM17 to cut oncogenic TGF-α, promoting tumor progression

These findings collectively suggest that PPP1R14D may serve as both a potential prognostic factor and therapeutic target in cancer treatment.

What are the optimal experimental approaches for PPP1R14D knockdown studies?

Based on published research methodologies, effective PPP1R14D knockdown can be achieved using lentiviral-mediated shRNA delivery. Successful approaches include:

• Vector selection: The GV248 lentiviral vector has been effectively used for PPP1R14D knockdown

• shRNA sequence design: The following sequences have demonstrated efficacy:

  • shPPP1R14D-1: 5′-TAG ATC CAT GAG AGC TTC CAG-3′

  • shPPP1R14D-2: 5′-AAC TTG AGC ATC CAC CCA TTG-3′

  • With scramble control: 5′-TTC TCC GAA CGT GTC ACG T-3′

• Infection parameters:

  • Viral concentration: 4E+8TU/ml for shPPP1R14D constructs

  • MOI (multiplicity of infection): 20

  • Polybrene concentration: 4%

  • Infection duration: 72 hours before transferring to selective medium

• Validation methods: Knockdown efficiency should be verified using Western blot with PPP1R14D-specific antibodies at 1:500-1:2000 dilution .

After knockdown, functional assays including proliferation, migration (wound-healing), invasion assays, and cell cycle analysis can be performed to assess the effects of PPP1R14D reduction .

What methods are most effective for studying PPP1R14D phosphorylation status?

PPP1R14D's function as a PP1 inhibitor is dependent on its phosphorylation state, with inhibitory activity only occurring when the protein is phosphorylated . To effectively study PPP1R14D phosphorylation:

• Phospho-specific antibodies: While not specifically mentioned in the search results, phospho-specific antibodies would be the ideal tool for direct detection of phosphorylated PPP1R14D. These could be developed using synthetic phosphopeptides corresponding to the key phosphorylation sites.

• Phosphatase treatment controls: Compare samples with and without phosphatase treatment prior to Western blot analysis. A mobility shift may indicate phosphorylation status.

• Kinase activation/inhibition: Since PKC phosphorylation activates PPP1R14D , experiments manipulating PKC activity (using activators like PMA or inhibitors like staurosporine) can help determine phosphorylation-dependent functions.

• Mass spectrometry: For identification of specific phosphorylation sites, immunoprecipitate PPP1R14D and analyze by mass spectrometry to identify and quantify phosphorylated residues.

• Functional assays: Compare the PP1 inhibitory activity of wild-type versus phosphorylation-site mutants of PPP1R14D to confirm the functional importance of specific phosphorylation events.

How can PPP1R14D expression be correlated with clinical outcomes in cancer research?

To establish correlations between PPP1R14D expression and clinical outcomes, researchers have employed several approaches:

These approaches collectively provide robust methods for investigating the clinical relevance of PPP1R14D as a prognostic biomarker in cancer.

What are the optimal storage and handling conditions for PPP1R14D antibodies?

For maximum stability and performance of PPP1R14D antibodies, the following storage and handling recommendations should be followed:

• Storage temperature: Store at -20°C for up to one year from the date of receipt

• Buffer composition: Antibodies are typically supplied in PBS containing:

  • 50% Glycerol

  • 0.5% BSA (in some formulations)

  • 0.02% Sodium azide

  • pH 7.3

• Aliquoting: While some suppliers indicate that aliquoting is unnecessary for -20°C storage , dividing into small aliquots is generally recommended to avoid repeated freeze-thaw cycles that can compromise antibody performance

• Thawing procedure: Thaw antibodies slowly on ice rather than at room temperature to preserve protein integrity

• Working dilution preparation: Dilute only the amount needed for immediate use in appropriate buffer (typically PBS with 1-5% BSA or normal serum)

These conditions ensure maintained reactivity and specificity of the antibody over the storage period.

How can I verify the specificity of a PPP1R14D antibody?

Verifying antibody specificity is critical for ensuring reliable experimental results. For PPP1R14D antibodies, several validation methods are recommended:

• Positive controls: Use samples known to express PPP1R14D, such as:

  • COLO 320 cells

  • Mouse colon tissue

  • Rat colon tissue

• Knockdown/knockout controls: Compare antibody signal between:

  • Cells expressing PPP1R14D

  • Cells with PPP1R14D knockdown using validated shRNA constructs (e.g., shPPP1R14D-1, shPPP1R14D-2)

• Western blot analysis: Confirm a single band at approximately 21 kDa (the observed molecular weight of PPP1R14D)

• Antigen pre-absorption: Pre-incubate the antibody with the immunizing peptide before application to samples - specific signals should be eliminated

• Cross-reactivity assessment: Test the antibody on tissues/cells from multiple species to confirm expected reactivity patterns as specified by the manufacturer (human, mouse, rat)

• Immunoprecipitation validation: Use the antibody for immunoprecipitation followed by Western blot with another PPP1R14D antibody raised against a different epitope

These validation steps provide comprehensive evidence for antibody specificity before proceeding with critical experiments.

What controls should be included in experiments using PPP1R14D antibodies?

Proper experimental controls are essential for interpreting results with PPP1R14D antibodies:

• Positive tissue/cell controls:

  • Brain tissue (known to express PPP1R14D)

  • Intestinal/colon tissue (shown to express PPP1R14D)

  • COLO 320 cells (demonstrated to express detectable levels)

• Negative controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG at the same concentration as the primary antibody)

  • Tissues/cells known not to express PPP1R14D

• Expression manipulation controls:

  • Samples with PPP1R14D knockdown using validated shRNA

  • Overexpression controls where appropriate

• Loading controls for Western blot:

  • Housekeeping proteins (β-actin, GAPDH, etc.)

  • Total protein staining methods (Ponceau S, Coomassie, etc.)

• Signal specificity controls:

  • Secondary antibody-only controls

  • Blocking peptide competition assays

Including these controls systematically will enhance the reliability and interpretability of experimental results using PPP1R14D antibodies.

What are the optimal protocols for immunohistochemical detection of PPP1R14D?

Based on published methodologies, an optimized immunohistochemistry protocol for PPP1R14D detection includes:

• Sample preparation:

  • Paraffin-embedded tissue sections baked at 60°C for 3 hours

  • Dewaxing in xylene followed by hydration with gradient alcohol

• Antigen retrieval:

  • Sodium citrate solution (pH 6.0)

  • High-pressure heat treatment

• Endogenous peroxidase blocking:

  • Treatment with 3% H₂O₂

• Blocking non-specific binding:

  • 10% goat serum for 30 minutes at room temperature

• Primary antibody incubation:

  • PPP1R14D antibody diluted 1:200 in PBS

  • Incubation at 4°C overnight

• Secondary antibody and detection:

  • HRP-labeled secondary antibody (e.g., Envision system)

  • Incubation at 37°C for 30 minutes

  • Visualization with 3,3-diaminobenzidine (DAB)

• Counterstaining and mounting:

  • Hematoxylin counterstaining

  • Dehydration and mounting with appropriate medium

This protocol has been successfully employed to analyze PPP1R14D expression in cancer tissues and correlate with clinical parameters .

How can I analyze PPP1R14D involvement in cellular signaling pathways?

To investigate PPP1R14D's role in signaling pathways, particularly the PKCα/BRAF/MEK/ERK pathway implicated in cancer progression, consider these methodological approaches:

• Pathway component analysis after PPP1R14D manipulation:

  • Western blot analysis of phosphorylated and total PKCα, BRAF, MEK, and ERK proteins

  • Compare expression/phosphorylation levels between control and PPP1R14D knockdown/overexpression samples

• Downstream target assessment:

  • Evaluate expression of c-Myc, Cyclin E1, CDK2 (cell cycle regulators)

  • Measure MMP2, MMP9, Vimentin (migration/invasion markers)

• Pathway inhibitor studies:

  • Use specific inhibitors of PKCα, BRAF, MEK, or ERK

  • Determine if inhibition phenocopies PPP1R14D knockdown effects

  • Test if pathway inhibition blocks effects of PPP1R14D overexpression

• Phosphatase activity assays:

  • Measure PP1 activity in the presence/absence of PPP1R14D

  • Determine how PPP1R14D phosphorylation affects PP1 activity

• Co-immunoprecipitation:

  • Use PPP1R14D antibodies to pull down protein complexes

  • Identify pathway components that directly interact with PPP1R14D

• Functional read-outs:

  • Cell proliferation assays

  • Migration assays (wound healing)

  • Invasion assays

  • Cell cycle analysis by flow cytometry

These approaches provide comprehensive analysis of PPP1R14D's role in cellular signaling networks.

What is the potential of PPP1R14D as a therapeutic target in cancer?

Based on current research findings, PPP1R14D shows promise as a therapeutic target in cancer, particularly lung adenocarcinoma, for several reasons:

• Overexpression in cancer tissues: PPP1R14D is highly expressed in LUAD tissues compared to normal tissues , providing a cancer-specific target

• Correlation with poor prognosis: Higher PPP1R14D expression is associated with lower survival rates in LUAD patients , suggesting clinical relevance

• Functional significance: PPP1R14D knockdown studies have demonstrated:

  • Significant inhibition of cancer cell proliferation

  • Reduced migration and invasion capabilities

  • Induction of cell cycle arrest at G1 phase

  • Suppression of tumor growth in vivo

• Defined mechanism of action: PPP1R14D promotes cancer progression through activation of the PKCα/BRAF/MEK/ERK pathway , a well-characterized oncogenic signaling cascade with established inhibitors

• Unique regulatory function: As a phosphorylation-dependent inhibitor of PP1 , PPP1R14D represents a novel regulatory node that could be targeted with specific inhibitors

Potential therapeutic approaches could include:

• Development of small molecule inhibitors targeting the PPP1R14D-PP1 interaction

• Disruption of PPP1R14D phosphorylation to prevent its activation

• siRNA/shRNA-based therapies to reduce PPP1R14D expression

• Targeting upstream regulators of PPP1R14D expression or activation

Further research on PPP1R14D inhibition in preclinical models and development of specific targeting strategies will be crucial for advancing its potential as a therapeutic target.

How can PPP1R14D be studied in the context of tumor microenvironment interactions?

Investigating PPP1R14D's role in tumor microenvironment interactions represents an important frontier in cancer research. Methodological approaches could include:

• Co-culture systems:

  • Culture cancer cells (with/without PPP1R14D manipulation) with stromal cells, immune cells, or endothelial cells

  • Assess how PPP1R14D expression affects cross-talk between different cell types

• 3D organoid models:

  • Generate organoids from cancer tissues with varying PPP1R14D expression levels

  • Evaluate growth patterns, invasion capabilities, and response to treatment

• Immunohistochemical analysis of clinical samples:

  • Use multiplex immunohistochemistry with PPP1R14D antibodies alongside markers for immune cells, fibroblasts, and blood vessels

  • Correlate PPP1R14D expression with immune infiltration patterns

• Secretome analysis:

  • Compare secreted factors from cells with different PPP1R14D expression levels

  • Identify how PPP1R14D affects the production of cytokines, chemokines, and growth factors that modulate the tumor microenvironment

• In vivo models with immune system evaluation:

  • Use immunocompetent mouse models bearing tumors with manipulated PPP1R14D expression

  • Assess tumor-infiltrating lymphocytes and myeloid cell populations

• Extracellular matrix (ECM) interaction studies:

  • Investigate how PPP1R14D affects production of matrix metalloproteinases (MMPs) and ECM remodeling

  • Determine effects on cell-ECM adhesion properties

These approaches would provide insights into how PPP1R14D contributes to tumor-stroma interactions and potentially identify new therapeutic opportunities targeting these interactions.